Condition: Duchenne Muscular Dystrophy · Duchenne · DMD · Sponsor: Satellos Bioscience, Inc.
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.
This description comes directly from the study's public registry record.
Satellos Medical Information · +1 647-660-1780 · medicalinfo@satellos.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| Colorado Children's | Aurora, Colorado, United States | Recruiting |
| Lurie Children's | Chicago, Illinois, United States | Recruiting |
| UMass Memorial Medical Center | Worcester, Massachusetts, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
| Seattle Children's | Seattle, Washington, United States | Recruiting |
| Children's Hospital at Westmead | Westmead, New South Wales, Australia | Not Yet Recruiting |
| Royal Children's Hospital Melbourne | Melbourne, Victoria, Australia | Recruiting |
| Hôpital De La Citadelle (CHR) | Liège, Liège, Belgium | Recruiting |
| UZ Gent | Ghent, Oost-Vlaanderen, Belgium | Recruiting |
| Children's Hospital Eastern Ontario | Ottawa, Ontario, Canada | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07287189